uniQure (NASDAQ:QURE) CFO Sells $33,009.12 in Stock

uniQure (NASDAQ:QURE) CFO Christian Klemt sold 2,916 shares of the company’s stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $11.32, for a total transaction of $33,009.12. Following the completion of the sale, the chief financial officer now owns 155,168 shares in the company, valued at approximately $1,756,501.76. This trade represents a 1.84 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Christian Klemt also recently made the following trade(s):

• On Tuesday, February 25th, Christian Klemt sold 14,341 shares of uniQure stock. The stock was sold at an average price of $10.70, for a total transaction of $153,448.70.
• On Monday, December 9th, Christian Klemt sold 1,796 shares of uniQure stock. The shares were sold at an average price of $7.55, for a total transaction of $13,559.80.

uniQure Trading Up 8.9 %

Shares of QURE stock opened at $13.15 on Friday. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. uniQure has a 12-month low of $3.73 and a 12-month high of $19.18. The stock has a market capitalization of $640.73 million, a P/E ratio of -2.65 and a beta of 0.38. The firm’s 50 day moving average is $15.05 and its 200 day moving average is $9.81.

Analyst Ratings Changes

A number of research firms have recently commented on QURE. Royal Bank of Canada reiterated an “outperform” rating and set a $24.00 price target on shares of uniQure in a report on Tuesday, January 21st. Leerink Partners increased their price target on shares of uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a report on Wednesday, December 11th. Guggenheim reiterated a “buy” rating on shares of uniQure in a report on Wednesday, December 11th. Cantor Fitzgerald increased their price target on shares of uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a report on Tuesday, December 10th. Finally, Wells Fargo & Company cut their price target on shares of uniQure from $35.00 to $30.00 and set an “equal weight” rating on the stock in a report on Friday. One analyst has rated the stock with a sell rating, three have assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $38.89.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. RTW Investments LP bought a new position in uniQure in the third quarter worth approximately $49,000. China Universal Asset Management Co. Ltd. raised its position in uniQure by 57.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 3,663 shares during the period. Atria Investments Inc bought a new position in uniQure in the third quarter worth approximately $53,000. Quarry LP bought a new position in uniQure in the third quarter worth approximately $58,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in uniQure in the third quarter worth approximately $69,000. 78.83% of the stock is currently owned by institutional investors.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.